AI-generated summary
The authors randomized 43 patients with hypothyroidism from chronic autoimmune thyroiditis to 10 sessions of low-level laser therapy at 830 nm or placebo, twice weekly. They report that serum TGF-β1 rose significantly more in the laser group than in the placebo group 30 days after treatment, with the association described as preliminary and requiring confirmation.
- Participants
- 43
- Who or what was studied
- Patients with hypothyroidism caused by chronic autoimmune thyroiditis who had a history of levothyroxine therapy
- Wavelengths
- 830 nm
- Limits stated in the abstract
- The authors state that future studies of TGF-β1 gene expression in thyroid tissue are needed to confirm these findings.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 830 nm
- Power
- 50 mW
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Laser, Placebo-controlled, Fluence, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.